Mostrando 7 resultados de: 7
Publisher
Journal of the International AIDS Society(2)
American Journal of Epidemiology(1)
Annals of Internal Medicine(1)
Clinical Infectious Diseases(1)
JMIR Public Health and Surveillance(1)
Área temáticas
Enfermedades(5)
Problemas sociales y servicios a grupos(5)
Medicina y salud(4)
Fuerzas aéreas y otras fuerzas especializadas(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Área de conocimiento
Epidemiología(3)
Infección(3)
Salud pública(2)
Estudios de género(1)
Salud Pública(1)
Origen
scopus(7)
Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study
ArticleAbstract: We estimated the trends and correlates of vaccine hesitancy and its association with subsequent vaccPalabras claves:Covid-19 pandemic, COVID-19 vaccine racial/ethnic disparities, COVID-19 vaccine uptake, Longitudinal cohort study, vaccine delay, Vaccine hesitancy, vaccine hesitancy trends, vaccine refusalAutores:Berry A., Chang M., Grov C., Kochhar S., Kulkarni S.G., Maroko A.R., Matthew L. Romo, Nash D., Parcesepe A.M., Poehlein E., Rane M.S., Robertson M.M., Westmoreland D.A., You W., Zimba R.Fuentes:scopusDisparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity An Observational Study
ArticleAbstract: Background: The transition to dolutegravir-containing antiretroviral therapy (ART) in low- and middlPalabras claves:Autores:Avihingsanon A., Azwa I., Bernard C., Bijker R., Brazier E., Bui H.V., Cahn P., Cardoso S.W., Castelnuovo B., Cesar C., Chaiwarith R., Chan Y.J., Chitalikar A., Choi J.Y., Chumla L., Cortés C.P., Dell'Isola E., Ditangco R., Do C.D., Edwards J.K., Ezhilarasi C., Fink V., Gaikwad S., Gani Y.M., Gatechompol S., Grinsztejn B., Han N., Humphrey J.M., Imran D., Jiamsakul A., Joshi K., Kamarulzaman A., Kambua P., Kantipong P., Ke E., Kelvin E.A., Khol V., Khuwuwan S., Kiertiburanakul S., Kim J.M., Ku W.W., Kumarasamy N., Kunzekwenyika C., Lam W., Law M.G., Lee L.S., Lee M.P., Li P.C.K., Lim P.L., Ly P.S., Maina M.W., Mationg M.L., Matthew L. Romo, Merati T.P., Musick B.S., Na S., Nash D., Ng O.T., Ngo A.V., Nguyen D.T., Nguyen D.T.H., Nguyen K.V., Nguyen L.T., Nishijima T., Nuket K., Oka S., Panczak R., Pasayan M.K., Patel R.C., Penner J., Perez H., Petersen B., Phadungphon C., Phanuphak P., Phuphuakrat A., Ponnampalavanar S., Praparattanapan J., Pujari S., Ross J.L., Rudi N.B., Rupasinghe D., Sanmeema N., Sirisanthana T., Sohn A.H., Sued O., Syed Omar S.F., Tanuma J., Valiente J., Widhani A., Wirawan D.N., Wong H.Y., Wools-Kaloustian K.K., Wu P.C., Wyka K., Yamamoto C., Yap J.K., Yuliana F., Yunihastuti E., Zhang F.J., Zhao H.X.Fuentes:scopusOnchocerciasis and epilepsy: a causal relationship?
OtherAbstract:Palabras claves:Autores:Matthew L. Romo, Nash D.Fuentes:scopusPatterns of SARS-CoV-2 Testing Preferences in a National Cohort in the United States: Latent Class Analysis of a Discrete Choice Experiment
ArticleAbstract: Background: Inadequate screening and diagnostic testing in the United States throughout the first sePalabras claves:cohort, covid-19, diagnostic, discrete choice, Discrete Choice Experiment, latent class analysis, pattern, Preference, PUBLIC HEALTH, SARS-COV-2, TESTING, transmission, trend, UNITED STATES, Uptake, VaccineAutores:Berry A., Grov C., Kochhar S., Kulkarni S.G., Maroko A.R., Matthew L. Romo, Mirzayi C., Nash D., Parcesepe A.M., Rane M.S., Robertson M.M., Waldron L., Westmoreland D.A., You W., Zimba R.Fuentes:scopusTrends in demographic and clinical characteristics and initiation of antiretroviral therapy among adult patients enrolling in HIV care in the Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018
ArticleAbstract: Introduction: The Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) isPalabras claves:ÁFRICA, ARV, Cohort Studies, HIV care continuum, HIV epidemiology, Low- and middle-income countriesAutores:Addison D., Adedimeji A., Adedimeji A.A., Ajeh R., Akele C., Amadou D., Anastos K., Ayinkamiye N., Balkissou A.D., Baransaka E., Barasukana P., Benekigeri C., Benwi M., Biziragusenyuka J., Brazier E., Bukuru H., Busingye L., Butera A.M., Diafouka M., Dilorenzo M., Dzudie A., Ekat M.H., Ekembe C., Ewanoge A.N., Fuhngwa N., Gasana J., Gateretse P., Habarurema E., Habiryayo T., Hoover D.R., Igirimbabazi J., Ingabire C., Ingabire M.G., Jones H., Kabahizi J., Kabanda E., Kagimbana J.C., Kankindi C., Kanyabwisha F., Kelvin E.A., Kendowo E., Kim H.Y., Kitetele F., Kubwimana G., Kulkarni S.G., Lelo P., Mafou A., Manirakiza M., Matthew L. Romo, Mbuh A., Mbuh T., Moki C., Muhayimpundu R., Muhoza B., Mukamusana D., Munezero A.M.M., Munezero J., Munyaneza A., Murchison L., Murenzi G., Musabyimana F., Musaninyange J., Mwiza F., Nahimana T., Nash D., Ndamijimana E., Ndikumwenayo F., Ndoli Y., Ndumuhire J., Nforniwe D.N., Ngamani M.L., Ngassam E., Nitereka V., Niyongabo T., Njie K.T., Nkome V., Nsanzimana S., Nsonde D., Nyirabahutu M.G., Nyiraneza M.L., Okitolonda E.W., Pélagie N., Remera E., Ross J., Rwibasira G.N., Sandjong F., Shi Q., Shyaka C., Sinayobye J.d.A., Tabala M., Tchassem E., Tsi K.A., Tuyisenge L., Tuyisenge P., Twizere C., Umumararungu E., Uwakijijwe B., Uwamahoro O., Yone E.W.P., Yotebieng M.Fuentes:scopusViral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa
ArticleAbstract: Background: Dolutegravir is being rolled out globally as part of preferred antiretroviral therapy (APalabras claves:antiretroviral agents, clinical decision-making, HIV integrase inhibitors, prognosis, Viral loadAutores:Diero L., Edwards J.K., Kasozi C., Kelvin E.A., Lelo P., Matthew L. Romo, Murenzi G., Musick B.S., Nash D., Odhiambo F., Semeere A.S., Sohn A.H., Urassa M., Wools-Kaloustian K.K., Wyka K.Fuentes:scopusReal-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa
ArticleAbstract: Introduction: Dolutegravir is being scaled up globally as part of antiretroviral therapy (ART), butPalabras claves:antiretroviral agents, antitubercular agents, drug interactions, HIV integrase inhibitors, Observational Study, rifampinAutores:Brazier E., Chimbetete C., De Waal R., Diero L., Dzudie A., Ezechi O.C., Fenner L., Kunzekwenyika C., Lelo P., Mahambou-Nsondé D., Matthew L. Romo, Muhairwe J.A., Murenzi G., Muyindike W.R., Nash D., Rafael I., Sekaggya-Wiltshire C., Shah N.S., Tiendrebeogo T., Twizere C., Wools-Kaloustian K.K., Yotebieng M.Fuentes:scopus